BioNexus Gene Lab (BGLC) Market Capitalization (2021 - 2026)

BioNexus Gene Lab has disclosed Market Capitalization across 6 years of filings, most recently posting $3.6 million for Q2 2026.

• In Q2 2026, Market Capitalization fell 33.81% year-over-year to $3.6 million; the TTM figure through Jun 2026 stood at $3.6 million (down 33.81% YoY), while the FY2025 annual figure was $7.3 million, up 47.0% from the prior year.
• Market Capitalization came in at $3.6 million for Q2 2026 at BioNexus Gene Lab, down from $4.0 million in the prior quarter.
• In the past five years, Market Capitalization ranged from a high of $460.7 million in Q2 2023 to a low of $3.6 million in Q2 2026.
• Average Market Capitalization over 5 years is $82.6 million, with a median of $9.6 million recorded in 2023.
• Year-over-year, Market Capitalization soared 132.64% in 2023 and slumped 98.18% in 2024.
• Over 5 years, Market Capitalization stood at $165.0 million in 2022, then slumped by 94.33% to $9.4 million in 2023, then slumped by 46.72% to $5.0 million in 2024, then surged by 47.0% to $7.3 million in 2025, then plunged by 50.63% to $3.6 million in 2026.
• Per Business Quant data, the three most recent Market Capitalization figures were $3.6 million in Q2 2026, $4.0 million in Q1 2026, and $7.3 million in Q4 2025.